Antibodies to human angiopoietin-like protein 3: A patent evaluation of WO2012174178

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 1, 2014, Pages 113-119

  Nakajima, Katsuyuki ^a   Kobayashi, Junji ^b  

^a GUNMA UNIVERSITY   (Japan)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

Antibody therapy; Familial combined hypolipidemia; Hepatic triglyceride lipase; Human angiopoietin like protein 3; Lipid disorders; Lipoprotein lipase; Remnant lipoproteins; Triglyceride

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; ANTILIPEMIC AGENT; CHOLESTEROL ESTER TRANSFER PROTEIN; H 4H 1276S; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL (TOPIC); CROSS REACTION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; GENE DOSAGE; HETEROZYGOSITY; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA; HYPOLIPEMIA; LIPID METABOLISM; LIPOPROTEIN METABOLISM; NONHUMAN; NONSENSE MUTATION; PHENOTYPE; POSTPRANDIAL STATE; THERAPY EFFECT; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOPOIETINS; ANIMALS; ANTIBODIES; BIOLOGICAL MARKERS; CHOLESTEROL; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYPOLIPIDEMIC AGENTS; LEGISLATION, DRUG; LIPOPROTEIN LIPASE; PATENTS AS TOPIC; TRIGLYCERIDES;

EID: 84890392586     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2013.842555     Document Type: Article

References (18)

1. Koishi R, Ando Y, Ono M, et al. Angptl3 regulates lipid metabolism in mice. Nat Genet 2002;30(2):151-7
2. Shimizugawa T, Ono M, Shimamura M, et al. ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002;277:33742-8
3. Fujimoto K, Koishi R, Shimizugawa T, Ando Y. Angptl3-null mice show low plasma lipid concentrations by enhanced lipoprotein lipase activity. Exp Anim 2006;55:27-34
4. Ono M, Shimizugawa T, Shimamura M, et al. Protein region important for regulation of lipid metabolism in angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem 2003;278:41804-9
5. Moon HD, Nakajima K, Kamiyama K, et al. Higher frequency of abnormal serum angiopoietin-like protein 3 than abnormal cholesteryl ester transfer protein in Japanese hyperalphalipoproteinemics. Clin Chim Acta 2008;398:93-104
6. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466:707-13
7. Marti'n-Campos JM, Roig R, Mayoral C, et al. Identification of a novel mutation in the ANGPTL3 gene in two families diagnosed of familial hypobetalipoproteinemia without APOB mutation. Clin Chim Acta 2012;413:552-5
8. Minicocci I, Montali A, Robciuc MR. Mutations in the ANGPTL3 gene and familial combined hypolipidemia: A clinical and biochemical characterization. J Clin Endocrinol Metab 2012;97:E1266-75
9. Musunuru K, Pirruccello JP, Do R, et al. Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. N Engl J Med 2010;363:2220-7
10. Nakajima K, Kobayashi J, Mabuchi H, et al. Association of angiopoietin-like protein 3 with hepatic triglyceride lipase and lipoprotein lipase activities in human plasma. Ann Clin Biochem 2010;47:423-31
11. Stanhope KL, Schwarz JM, Keim NL, et al. Effects of consuming fructose- or glucose-sweetened beverages for 10 weeks on lipids, insulin sensitivity and adiposity. J Clin Invest 2009;119:1322-34
12. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012;380:29-36
13. Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci 2012;8:310-27
14. King A. Lipids: Antibodies against PCSK9-A new era of therapy. Nat Rev Cardiol 2013;10:1
15. Yamashita S, Matsuzawa Y. Where are we with probucol: A new life for an old drug? Atherosclerosis 2009;207:16-23; 27
16. Miida T, Seino U, Miyazaki O, et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: Putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 2008;200:329-35
17. Homma Y, Moriguchi EH, Sakane H, et al. Effects of probucol on plasma lipoprotein subfractions and activities of lipoprotein lipase and hepatic triglyceride lipase. Atherosclerosis 1991;88:175-81
18. Favari E, Zanotti I, Zimetti F, et al. Probucol inhibits ABCA1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol 2004;24:2345-50